← Back to Analyst Consensus 
XERS Buy
Xeris Biopharma Holdings, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 6, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 10, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Aug 20, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Mar 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jan 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Dec 9, 2025 | Barclays | initiate | — → Overweight | $9 | 53% |
| Nov 7, 2025 | Oppenheimer | maintain | Outperform → Outperform | $18 | 52% |
| Nov 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Nov 7, 2025 | Piper Sandler | maintain | Neutral → Neutral | $8 | 54% |
| Oct 29, 2025 | Oppenheimer | maintain | Outperform → Outperform | $18 | 52% |
| Sep 17, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Aug 19, 2025 | Leerink Partners | maintain | Outperform → Outperform | $9 | 51% |
| Aug 8, 2025 | Craig-Hallum | maintain | Buy → Buy | $11 | 54% |
| Aug 8, 2025 | Oppenheimer | maintain | Outperform → Outperform | $8 | 52% |
| Jun 5, 2025 | Leerink Partners | maintain | Outperform → Outperform | $7 | 51% |
| May 9, 2025 | Oppenheimer | maintain | Outperform → Outperform | $7 | 52% |
| Mar 7, 2025 | Piper Sandler | reiterate | Neutral → Neutral | $4 | 54% |
| Mar 7, 2025 | Leerink Partners | maintain | Outperform → Outperform | $6 | 51% |
| Mar 7, 2025 | Craig-Hallum | maintain | Buy → Buy | $6.5 | 54% |
| Mar 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jan 29, 2025 | Jefferies | reiterate | Buy → Buy | $6 | 52% |
| Nov 11, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $6.6 | 44% |
| Nov 11, 2024 | Piper Sandler | downgrade | Overweight → Neutral | $3 | 54% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| May 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| May 10, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $3 | 54% |
| Mar 28, 2024 | Oppenheimer | initiate | — → Outperform | $5 | 52% |
| Mar 7, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $6 | 44% |
| Nov 13, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $5.5 | 44% |
| Nov 10, 2023 | Piper Sandler | maintain | Overweight → Overweight | $4 | 54% |
| Aug 28, 2023 | Craig-Hallum | initiate | — → Buy | $4.5 | 54% |
| Aug 9, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| May 10, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Mar 9, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $6 | 44% |
| Jan 27, 2023 | SVB Leerink | maintain | — → Outperform | $5 | — |
| Apr 28, 2022 | Craig-Hallum | initiate | — → Buy | $6.5 | 54% |
| Mar 16, 2022 | Mizuho | maintain | — → Buy | $6 | 52% |
| Feb 16, 2022 | SVB Leerink | maintain | — → Outperform | $6 | — |
| Dec 31, 2021 | SVB Leerink | maintain | — → Outperform | $8 | — |
| Dec 31, 2021 | HC Wainwright & Co. | maintain | — → Buy | $5.4 | 44% |
| Nov 17, 2021 | SVB Leerink | initiate | — → Outperform | $6 | — |
| Oct 29, 2021 | HC Wainwright & Co. | initiate | — → Buy | $4 | 44% |
Price Target Trend
Apr 24, 2026 Oct 27, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days